April 22, 2024

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

AMENDMENTS

GYNECOLOGIC

NRG-GY028: Amendment 3; version date: March 26, 2024 (posted on CTSU)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANKS

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. BREAST

NRG-BR007/DEBRA: Study overview webinars are being held via Microsoft Teams on April 19 from 2-3pm ET and April 26 from 12-1pm ET. Please see the memorandum, dated March 25, 2024, (posted on CTSU) for details and how to register for one of the sessions. Please note: Google Chrome is the preferred browser to register for the webinars. 

NRG-BR008/HERO: Study overview webinars are being held via Microsoft Teams on April 30 at 3pm ET and May 1 at 11am ET. Please see the memorandum, dated April 1, 2024, (posted on CTSU) for details and how to register for one of the sessions. Please note: Google Chrome is the preferred browser to register for the webinars.

4. CANCER PREVENTION & CONTROL

NRG-CC005/FORTE: Listing of Spanish Patient-Directed Materials – April 2024 (posted on CTSU)  

NRG-CC010: The study is open to NRG sites in Japan and South Korea. The optional biospecimen collection does not apply to sites participating in these countries.

5. GENITOURINARY

NRG-GU009: Updated Pill Diary and CIRB approval are posted on CTSU.

6. GYNECOLOGIC

GOG-0210: Reminder: Biospecimens, biomarker data, clinical data, and epidemiologic data are available for request. Please visit the NRG Oncology website for more information on this important study with the overall goal of improving the outcome and/or quality of life for patients with endometrial cancer.

NRG-GY026 is quickly approaching the initial accrual cap of 68 patients with Stage I or Stage II disease. Once 68 stage I-II patients are enrolled, accrual will be suspended for this group to evaluate responses. The study will remain open to accrual for patients with Stage III or Stage IV disease only. Refer to Section 14.5 for a more detailed description of the statistical plan.

NRG-GY031: Please note, there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

NRG-GY033 has nearly met the first stage of accrual. Accrual is currently at 13. Once 17 patients are enrolled, accrual will be suspended to evaluate responses. Refer to Sections 13.4.1 and 13.4.2 for a more detailed description of the statistical plan. Please check accrual on CTSU before enrolling patients.

7. HEAD & NECK

NRG-HN008

Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important.

8. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005, NRG-BR009, NRG-CC011, and NRG/SWOG S1914. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, May 8, 2024.

Drug Safety updates have been issued for the following studies:

Application Deadline Extension - Chair, NRG Oncology Developmental Therapeutics Gynecologic Phase I Subcommittee

NEW Application Deadline: April 22, 2024.We are seeking nominations for the position of Chair, NRG Developmental Therapeutics Gynecologic Phase I Subcommittee. This NRG subcommittee sits within the NRG Developmental Therapeutics Committee, a Scientific Core Committee, and aides in cross-group collaboration and engagement around disease/target-oriented Phase I trials. Read more

NRG Oncology Confidential Member Survey

Please read our survey FAQ’s. All NRG Members should have received an email from the University of Chicago’s Survey Lab containing a unique survey link. If you have not already completed the survey, please check your inbox and possibly your spam/junk mailbox for the email so that you can help us collect this important information. Please send any additional questions to nrg-broadcasts@nrgoncology.org.

NRG Oncology is pleased to announce the following abstract accepted for presentation at the American Society of Clinical Oncology (ASCO) 2024 symposium. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

ACCEPTED ABSTRACTS

Bredel M, Espinosa L, Pugh SL, Chakravarti A. NFKBIA deletions reshape the epigenome antithetical to the IDH mutation and portend poor prognosis in diffuse gliomas. ASCO (American Society of Clinical Oncology). Poster presentation. 5/31/2024.

Please note the following upcoming meetings and abstract submission deadlines



UPCOMING MEETINGS

American Association for Thoracic Surgery (AATS); Apr 27-30, 2024; Toronto, ON

American Brachytherapy Society (ABS) World Congress; Jul 10-13, 2024; National Harbor, MD

American Head and Neck Society (AHNS); May 15-16, 2024; Chicago, IL

American Radium Society (ARS); May 2-5, 2024; Palm Springs, CA

American Society of Clinical Oncology (ASCO); May 31-Jun 4, 2024; Chicago, IL

American Society of Colon and Rectal Surgeons (ASCRS); Jun 1-4, 2024; Baltimore, MD

European Society for Medical Oncology (ESMO) Breast Cancer; May 15-17, 2024; Berlin, Germany

European Society for Medical Oncology (ESMO) Gastrointestinal; Jun 26-29, 2024; Munich, Germany

European Society for Medical Oncology (ESMO) Gynaecological; Jun 20-22, 2024; Florence, Italy

European Society for Radiotherapy and Oncology (ESTRO); May 3-7, 2024; Glasgow, Scotland

International Society for Quality-of-Life Research (ISOQOL); Oct 13-16, 2024; Cologne, Germany

Society for Clinical Trials (SCT); May 19-22, 2024; Boston, MA

Western Association of Gynecologic Oncologists (WAGO); Jun 12-15, 2024; Seattle, WA

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Society for Radiation Oncology (ASTRO); Sep 29-Oct 2, 2024; Washington, DC; LBA Jul 12, 2024

EORTC-NCI-AACR Symposium on Molecular Targets and therapies; Oct 23-25, 2024; Barcelona, Spain; due to publications committee Jun 13, 2024; submission deadline Jun 27, 2024; LBA Sep 26, 2024

European Society for Medical Oncology (ESMO); Sep 13-17, 2024; Barcelona, Spain; due to publications committee Apr 23, 2024; submission deadline May 7, 2024, 21:00 CET; LBA Aug 7, 2024, 21:00 CET (placeholder required)

International Gynecologic Cancer Society (IGCS); Oct 16-18, 2024; Dublin, Ireland; submission deadline Apr 30, 2024, 23:59 IST; LBA Jul 2, 2024, 23:59 IST



Radiological Society of North America (RSNA); Dec 1-5, 2024; Chicago, IL; submission deadline May 1; 2024

San Antonio Breast Cancer Society (SABCS); Dec 10-14, 2024; San Antonio, TX; due to publications committee Jun 26, 2024; submission deadline Jul 10, 2024, 11:59 pm CT; LBA Sep 30, 2024, 11:59 pm CT

Society for Immunotherapy of Cancer (SITC); Nov 6-10, 2024; Houston, TX; due to publications committee May 15, 2024; submission deadline Jun 27, 2024